<DOC>
	<DOCNO>NCT00343447</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Vaccines may help body build effective immune response kill cancer cell . Giving cyclophosphamide rituximab together vaccine therapy may kill cancer cell . PURPOSE : This randomized phase II trial study cyclophosphamide rituximab follow two different schedule vaccine therapy compare well work treat patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Cyclophosphamide Rituximab Followed By Vaccine Therapy Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy toxicity cyclophosphamide rituximab patient previously untreated , high-risk chronic lymphocytic leukemia . - Determine , preliminarily , efficacy toxicity early v delay administration vaccine therapy comprise KGEL autologous tumor cell cyclophosphamide rituximab patient . - Compare magnitude T-cell response early v delay administration vaccine rituximab cyclophosphamide correlate response extent immune reconstruction . OUTLINE : This randomized phase II study patient asymptomatic minimally symptomatic , untreated CLL poor-risk feature . Patients undergo peripheral blood collection vaccine production . Patients receive rituximab IV least 4 hour day 1 2 course 1 day 1 subsequent course cyclophosphamide IV 1 hour day 1 . Treatment rituximab cyclophosphamide repeat every 21 day 6 cycle absence disease progression . Patients undergo evaluation 4 week completion rituximab cyclophosphamide . Patients achieve partial complete response randomize 1 2 vaccine treatment arm . - Arm I ( early administration ) : Beginning 2 week evaluation , patient receive vaccine therapy comprise autologous tumor admix allogeneic vaccine ( KGEL ) produce sargramostim ( GM-CSF ) autologous tumor cell intradermally . Treatment repeat every 3 week 6 course absence unacceptable toxicity . - Arm II ( late administration ) : Beginning 20 week evaluation , patient receive vaccine therapy comprise KGEL autologous tumor cell intradermally . Treatment repeat every 3 week 6 course absence unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month disease progression . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia ( CLL ) Meets 1 follow highrisk feature : 17p deletion fluorescent situ hybridization ( FISH ) 11q deletion FISH Unmutated immunoglobulin heavy chain variable region ( IgVH ) gene , define ≥ 98 % homology germline Clinical Laboratory Improvement Act ( CLIA ) approve laboratory Any stage disease Previously untreated disease Not require immediate treatment Absolute lymphocyte count ≥ 20,000/mm³ PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 2 mg/dL ( unless secondary obstructive cholestasis lymphadenopathy Gilbert 's disease ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require oral intravenous antibiotic No autoimmune disorder ( e.g. , autoimmune hemolytic anemia ) require corticosteroid start study vaccination No malignancy except nonbasal cell skin cancer , carcinoma situ cervix , tumor treat curative intent ≥ 2 year ago PRIOR CONCURRENT THERAPY : No prior therapy CLL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>